C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients, may undergo extravascular hemolysis reducing clinical benefits. Despite the uniform deficiency of CD55 and of CD59, there are always two distinct populations of PNH RBCs, with (C3+) and without (C3-) C3 binding.
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes / Sica, Michela; Rondelli, Tommaso; Ricci, Patrizia; De Angioletti, Maria; Risitano, ANTONIO MARIA; Notaro, Rosario. - In: JOURNAL OF HEMATOLOGY & ONCOLOGY. - ISSN 1756-8722. - 10:1(2017), p. 126. [10.1186/s13045-017-0496-x]
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes
RISITANO, ANTONIO MARIA;
2017
Abstract
C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients, may undergo extravascular hemolysis reducing clinical benefits. Despite the uniform deficiency of CD55 and of CD59, there are always two distinct populations of PNH RBCs, with (C3+) and without (C3-) C3 binding.| File | Dimensione | Formato | |
|---|---|---|---|
|
#111 Sica, J Hematol Oncol 2017.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
1.23 MB
Formato
Adobe PDF
|
1.23 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
